{"id":1014,"date":"2026-03-06T17:35:28","date_gmt":"2026-03-06T16:35:28","guid":{"rendered":"https:\/\/animalwelfare.iph-multisite.berta-bewegt.ch\/?page_id=1014"},"modified":"2026-03-09T14:52:58","modified_gmt":"2026-03-09T13:52:58","slug":"5-ouverture-et-souplesse-des-autorites","status":"publish","type":"page","link":"https:\/\/animalwelfare.interpharma.ch\/fr\/sujets\/beispiele\/developpement-de-vaccins-et-de-tests-pour-le-sars-cov-2\/5-ouverture-et-souplesse-des-autorites\/","title":{"rendered":"5. Ouverture et souplesse des autorit\u00e9s"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">5. Ouverture et souplesse des autorit\u00e9s<\/h2>\n\n\n\n<p>En plus des diverses formes de coop\u00e9ration, des processusacc\u00e9l\u00e9r\u00e9s et simplifi\u00e9s en phase clinique ont aid\u00e9 \u00e0 contr\u00f4lerplus rapidement l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des vaccins. En semontrant ouvertes \u00e0 l\u2019acc\u00e9l\u00e9ration des processus, les autorit\u00e9sont contribu\u00e9 \u00e0 l\u2019autorisation d\u2019un premier vaccin en un tempsrecord. Malgr\u00e9 l\u2019urgence extr\u00eame, la s\u00e9curit\u00e9 (et l\u2019efficacit\u00e9)restent les priorit\u00e9s absolues. Mais les fabricants ont pu r\u00e9aliserplusieurs processus de d\u00e9veloppement en parall\u00e8le. Ainsi,par exemple, a-t-on pu combiner diff\u00e9rentes phases d\u2019essaiscliniques. De m\u00eame, les entreprises pharmaceutiques ont recrut\u00e9au m\u00eame moment des volontaires pour plusieurs phasesdes essais cliniques. Si les travaux de recherche n\u2019avaient pasabouti, les pr\u00e9paratifs pr\u00e9coces et co\u00fbteux pour les phases ult\u00e9rieuresauraient \u00e9t\u00e9 vains. L\u2019\u00e9change avec les autorit\u00e9s a aussi\u00e9t\u00e9 intensifi\u00e9 et la proc\u00e9dure d\u2019autorisation acc\u00e9l\u00e9r\u00e9e de Swissmedic.Normalement, dans le cadre du processus d\u2019AMM,on rassemble les r\u00e9sultats des phases cliniques I-III pour lessoumettre au contr\u00f4le. Mais pour l\u2019AMM des vaccins contrele coronavirus, dans le cadre d\u2019un processus roulant, les diff\u00e9rentsessais ont \u00e9t\u00e9 soumis en continu \u00e0 Swissmedic qui lesa \u00e9galement contr\u00f4l\u00e9s en continu. Cela a permis d\u2019\u00e9viter desretards dans le processus d\u2019autorisation sans faire de concessionsen termes de s\u00e9curit\u00e9.<\/p>\n\n\n\n<p>Trente ans d\u2019exp\u00e9rience dans le domaine de la technologie \u00e0ARNm, une coop\u00e9ration internationale sans pr\u00e9c\u00e9dent entrela science, les entreprises pharmaceutiques et les start-upbiotechnologiques, ainsi que l\u2019acc\u00e9l\u00e9ration des proc\u00e9duresr\u00e9glementaires par les diverses autorit\u00e9s ont permis le d\u00e9veloppementde vaccins en un temps record. Mais la pand\u00e9miea \u00e9galement montr\u00e9 que, sans une utilisation responsabled\u2019animaux, cela n\u2019aurait pas \u00e9t\u00e9 possible.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>5. Ouverture et souplesse des autorit\u00e9s En plus des diverses formes de coop\u00e9ration, des processusacc\u00e9l\u00e9r\u00e9s et simplifi\u00e9s en phase clinique ont aid\u00e9 \u00e0 contr\u00f4lerplus rapidement l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des vaccins. En semontrant ouvertes \u00e0 l\u2019acc\u00e9l\u00e9ration des processus, les autorit\u00e9sont contribu\u00e9 \u00e0 l\u2019autorisation d\u2019un premier vaccin en un tempsrecord. Malgr\u00e9 l\u2019urgence extr\u00eame, la s\u00e9curit\u00e9 (et [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1038,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-1014","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>5. Ouverture et souplesse des autorit\u00e9s - animalwelfare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5. Ouverture et souplesse des autorit\u00e9s\" \/>\n<meta property=\"og:description\" content=\"5. Ouverture et souplesse des autorit\u00e9s En plus des diverses formes de coop\u00e9ration, des processusacc\u00e9l\u00e9r\u00e9s et simplifi\u00e9s en phase clinique ont aid\u00e9 \u00e0 contr\u00f4lerplus rapidement l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des vaccins. En semontrant ouvertes \u00e0 l\u2019acc\u00e9l\u00e9ration des processus, les autorit\u00e9sont contribu\u00e9 \u00e0 l\u2019autorisation d\u2019un premier vaccin en un tempsrecord. Malgr\u00e9 l\u2019urgence extr\u00eame, la s\u00e9curit\u00e9 (et [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/\" \/>\n<meta property=\"og:site_name\" content=\"animalwelfare\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T13:52:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/\",\"url\":\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/\",\"name\":\"5. Ouverture et souplesse des autorit\u00e9s - animalwelfare\",\"isPartOf\":{\"@id\":\"https:\/\/animalwelfare.interpharma.ch\/#website\"},\"datePublished\":\"2026-03-06T16:35:28+00:00\",\"dateModified\":\"2026-03-09T13:52:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/animalwelfare.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contenus\",\"item\":\"https:\/\/animalwelfare.interpharma.ch\/fr\/sujets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Exemple\",\"item\":\"https:\/\/animalwelfare.interpharma.ch\/fr\/sujets\/beispiele\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"D\u00e9veloppement de vaccins et de tests pour le SARS-CoV-2\",\"item\":\"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"5. Ouverture et souplesse des autorit\u00e9s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/animalwelfare.interpharma.ch\/#website\",\"url\":\"https:\/\/animalwelfare.interpharma.ch\/\",\"name\":\"animalwelfare\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/animalwelfare.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"5. Ouverture et souplesse des autorit\u00e9s - animalwelfare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/","og_locale":"fr_FR","og_type":"article","og_title":"5. Ouverture et souplesse des autorit\u00e9s","og_description":"5. Ouverture et souplesse des autorit\u00e9s En plus des diverses formes de coop\u00e9ration, des processusacc\u00e9l\u00e9r\u00e9s et simplifi\u00e9s en phase clinique ont aid\u00e9 \u00e0 contr\u00f4lerplus rapidement l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 des vaccins. En semontrant ouvertes \u00e0 l\u2019acc\u00e9l\u00e9ration des processus, les autorit\u00e9sont contribu\u00e9 \u00e0 l\u2019autorisation d\u2019un premier vaccin en un tempsrecord. Malgr\u00e9 l\u2019urgence extr\u00eame, la s\u00e9curit\u00e9 (et [&hellip;]","og_url":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/","og_site_name":"animalwelfare","article_modified_time":"2026-03-09T13:52:58+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/","url":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/","name":"5. Ouverture et souplesse des autorit\u00e9s - animalwelfare","isPartOf":{"@id":"https:\/\/animalwelfare.interpharma.ch\/#website"},"datePublished":"2026-03-06T16:35:28+00:00","dateModified":"2026-03-09T13:52:58+00:00","breadcrumb":{"@id":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/5-offenheit-und-flexibilitat-der-behorden\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/animalwelfare.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Contenus","item":"https:\/\/animalwelfare.interpharma.ch\/fr\/sujets\/"},{"@type":"ListItem","position":3,"name":"Exemple","item":"https:\/\/animalwelfare.interpharma.ch\/fr\/sujets\/beispiele\/"},{"@type":"ListItem","position":4,"name":"D\u00e9veloppement de vaccins et de tests pour le SARS-CoV-2","item":"https:\/\/animalwelfare.interpharma.ch\/themen\/beispiele\/impfstoff-und-testentwicklung-fur-sars-cov-2\/"},{"@type":"ListItem","position":5,"name":"5. Ouverture et souplesse des autorit\u00e9s"}]},{"@type":"WebSite","@id":"https:\/\/animalwelfare.interpharma.ch\/#website","url":"https:\/\/animalwelfare.interpharma.ch\/","name":"animalwelfare","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/animalwelfare.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=1014"}],"version-history":[{"count":2,"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1014\/revisions"}],"predecessor-version":[{"id":2858,"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1014\/revisions\/2858"}],"up":[{"embeddable":true,"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1038"}],"wp:attachment":[{"href":"https:\/\/animalwelfare.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=1014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}